Medpace Holdings

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Medpace Holdings reports robust Q4 earnings amidst challenging biotech environment

Medpace Holdings delivered strong financial results in Q4 2022, showcasing revenue and EBITDA growth. The company addressed challenges such as cancellations and client funding risks while emphasizing strategic selectivity and revenue growth. Opportunities for growth through share-taking strategies and operational improvements were highlighted.

Medpace Holdings reports stellar Q1 results and projects strong 2023 guidance

Medpace Holdings demonstrated robust financial performance in Q1 2023, marked by significant revenue growth, improved profitability, and a strong backlog conversion outlook.
While facing funding challenges, the company's strategic initiatives, including share repurchases and updated guidance, highlight its resilience and growth potential.
By capitalizing on increased RFP flow, program progression, and strong backlog metrics, Medpace aims to sustain its growth trajectory and enhance market position.

Medpace Holdings reports robust Q2 earnings and growth opportunities

Medpace Holdings (MEDP) delivered a strong Q2 performance with significant revenue growth, solid financial metrics, and a healthy backlog, positioning the company for future success.
While facing challenges related to customer concentration and operational aspects, Medpace can capitalize on opportunities to drive revenue expansion, enhance market share, and improve operational efficiency.
Overall, Medpace's Q2 earnings call reflects a positive outlook with a focus on growth strategies, operational excellence, and addressing potential challenges to drive long-term value for stakeholders.

Medpace Holdings reports robust Q3 performance and optimistic 2024 outlook

Medpace Holdings delivered strong financial results in Q3 2023, with notable revenue growth and increased backlog, despite modest EBITDA growth.
The company's operational strengths include robust demand, good retention rates, and a stable employee base, supporting its growth trajectory.
While facing potential challenges in managing rapid growth, Medpace Holdings has opportunities for expansion through market diversification and service enhancements.

Medpace Holdings reports robust Q4 earnings and outlines growth targets

Medpace Holdings delivered impressive financial results in Q4 2023, showcasing strong revenue growth, increased net income, and a healthy EBITDA, supported by new business awards and share repurchases.
While the company faces challenges in sustaining high growth rates and addressing uncertainties in project funding, its stable financial position and strategic initiatives provide a foundation for future growth.
With a positive outlook for 2024 and opportunities for expansion and market share gains, Medpace is well-positioned to navigate industry challenges and drive continued success in the clinical research sector.

Medpace Holdings reports robust Q1 performance and optimistic 2024 outlook

Medpace Holdings delivered impressive Q1 results, showcasing strong revenue growth and profitability metrics.
The company's strategic focus on efficiency and growth opportunities bodes well for future performance and sustained success.
While challenges exist, Medpace's positive outlook, stable funding environment, and strategic initiatives position it for continued growth and value creation.

Medpace Holdings reports robust Q2 growth despite project cancellations

Medpace Holdings delivered strong financial performance in Q2 2024, with notable revenue and EBITDA growth. While facing challenges with project cancellations impacting backlog, the company remains optimistic about its future prospects, driven by a robust pipeline of opportunities and strategic hiring plans.

Medpace Holdings reports strong Q3 earnings, eyes growth opportunities

Medpace Holdings delivered strong financial results in Q3 2024, with revenue growth, increased profitability, and a healthy backlog, setting a positive trajectory for future performance.
While facing challenges such as backlog cancellations and lower RFP flow, the company's stable pricing, strategic focus, and operational efficiency position it well for growth.
Opportunities lie in improving order intake, capital deployment optimization, and maintaining shareholder value through disciplined decision-making and market expansion.
Overall, Medpace Holdings' performance reflects resilience, strategic clarity, and potential for growth, underpinned by operational efficiency and financial stability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES, CA / ACCESSWIRE / August 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Can Participate In The Medpace Holdings Inc Securities Fraud Investigation With The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / August 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

MEDP Investors Can Participate In The Medpace Holdings Inc Securities Fraud Investigation With The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / August 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace") (NASDAQ:MEDP) concerning possible violations of federal securities laws. On July 22, 2024, after market hours, MedPace announced mixed financial results for the second quarter of 2024 and then slashed its revenue guidance for the third quarter and remainder of the year.

Shareholders that lost money on Medpace Holdings, Inc.(MEDP) should contact Levi & Korsinsky about Securities Fraud Investigation - MEDP

LOS ANGELES, CA / ACCESSWIRE / August 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

MEDP Investors Can Join The Medpace Holdings Inc Securities Fraud Investigation With The Schall Law Firm

NEW YORK--(BUSINESS WIRE)-- #Investigation--The law firm of Kirby McInerney LLP is investigating potential claims against Medpace Holdings, Inc. (“Medpace” or the “Company”) (NASDAQ: MEDP). The investigation concerns whether Medpace and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On July 22, 2024, Medpace released its second quarter 2024 financial results, significantly missing expect.

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Medpace Holdings, Inc. (MEDP)

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Medpace Holdings, Inc. (“Medpace” or the “Company”) (NASDAQ: MEDP) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Medpace investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securitie.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Medpace Holdings, Inc. (MEDP) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Medpace Holdings, Inc. (“Medpace” or the “Company”) (NASDAQ: MEDP) investors concerning the Company's possible violations of federal securities laws. On July 22, 2024, after market hours, Medpace released its second quarter 2024 financial results, significantly missing expectations. In an earnings call the following day, July 23, 2024, the Company stated that “cancellations were disproportiona.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Medpace Holdings, Inc. (MEDP) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Medpace Holdings, Inc. (“Medpace” or the “Company”) (NASDAQ: MEDP) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On July 22, 2024, after market hours, Medpace released its second quarter 2024 financial results, significantly missing expectations. In an earnings call the following da.

The Law Offices of Frank R. Cruz Announces Investigation of Medpace Holdings, Inc. (MEDP) on Behalf of Investors

LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medpace Holdings, Inc. ("Medpace" or "the Company") (NASDAQ:MEDP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

MEDP Investors Can Participate In The Medpace Holdings, Inc. Securities Fraud Investigation With The Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)--MEDP Investors Have Opportunity to Join Medpace Holdings, Inc. Securities Fraud Investigation with the Schall Law Firm.

MEDP Investors Have Opportunity to Join Medpace Holdings, Inc. Securities Fraud Investigation with the Schall Law Firm

NEW YORK, NY / ACCESSWIRE / July 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Medpace Holdings, Inc. ("Medpace") (NASDAQ:MEDP) concerning possible violations of federal securities laws. On July 22, 2024, after market hours, MedPace announced mixed financial results for the second quarter of 2024 and then slashed its revenue guidance for the third quarter and remainder of the year.

ATTENTION MEDP SHAREHOLDERS: Investors who lost money on Medpace Holdings, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 Reasons Growth Investors Will Love Medpace (MEDP)

Medpace Holdings, Inc. (NASDAQ:MEDP ) Q2 2024 Earnings Conference Call July 23, 2024 9:00 AM ET Company Participants Lauren Morris - Director of IR August Troendle - CEO Jesse Geiger - President Kevin Brady - CFO Conference Call Participants Eric Coldwell - Baird Max Smock - William Blair David Windley - Jefferies Daniel Leonard - UBS Ann Hynes - Mizuho Securities Charles Rhyee - TD Cowen Jack Wallace - Guggenheim Partners Justin Bowers - Deutsche Bank Operator Good day, ladies and gentlemen, and welcome to Medpace Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Medpace Holdings, Inc. (MEDP) Q2 2024 Earnings Call Transcript

NXP Semiconductors

U.S. stock futures were mixed this morning, with the Dow futures gaining around 20 points on Tuesday.

NXP Semiconductors Posts Mixed Q2 Results, Joins Medpace And Other Big Stocks Moving Lower In Tuesday Pre-Market Session

Medpace (MEDP) came out with quarterly earnings of $2.75 per share, beating the Zacks Consensus Estimate of $2.52 per share. This compares to earnings of $1.93 per share a year ago.

Medpace (MEDP) Tops Q2 Earnings Estimates

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Results Revenue for the three months ended June 30, 2024 increased 14.6% to $528.1 million, compared to $460.9 million for the comparable prior-year period. On a constant currency basis, revenue for the second quarter of 2024 increased 14.7% compared to the second quarter of 2023. Backlog as of June 30, 2024 in.

Medpace Holdings, Inc. Reports Second Quarter 2024 Results

Continued strength in backlog conversion rate is likely to have boosted Medpace's (MEDP) top line in the second quarter.

Backlog Conversion Likely to Aid Medpace's (MEDP) Q2 Earnings

Logitech

Investors will want to pay attention to several top-rated Zacks stocks that are set to report their quarterly results on Monday, July 22.

Top Stocks to Buy for Growth as Earnings Approach

Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Medpace Holdings, Inc. (MEDP) Hits Fresh High: Is There Still Room to Run?

Surgery Partners

Investors interested in stocks from the Medical Services sector have probably already heard of Surgery Partners (SGRY) and Medpace (MEDP). But which of these two companies is the best option for those looking for undervalued stocks?

SGRY vs. MEDP: Which Stock Is the Better Value Option?

The latest trading day saw Medpace (MEDP) settling at $443, representing a +1.84% change from its previous close.

Medpace (MEDP) Beats Stock Market Upswing: What Investors Need to Know

Medpace (MEDP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Medpace (MEDP) Upgraded to Strong Buy: Here's Why

Medpace Holdings, Inc. (MEDP) Hit a 52 Week High, Can the Run Continue?

In the latest trading session, Medpace (MEDP) closed at $405.33, marking a -0.53% move from the previous day.

Medpace (MEDP) Stock Sinks As Market Gains: Here's Why

CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its second quarter 2024 financial results after the market close on Monday, July 22, 2024. The Company will host a conference call the following morning, Tuesday, July 23, 2024, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10.

News for Medpace Holdings Stock (MEDP)